2013 Dana Foundation article - Psychiatric Drug Development: Diagnosing a Crisis

Here's the description, from the article itself:

"When it comes to funding drug research to treat depression, schizophrenia, anxiety, and other psychiatric disorders, the global pharmaceutical industry prefers to invest its research dollars in cancer, metabolism, autoimmunity, and other disease areas. This comes despite the fact that one in five Americans currently take at least one psychiatric drug and that mental disorders are recognized worldwide. The author traces the evolution of psychiatric drug development, the reasons for its retreat, and what needs to change to meet the growing demand."

Just a small warning: The print is a bit small, so if you can do so, you might want to enlarge it. Otherwise, it's a great read.

http://dana.org/Cerebrum/2013/Psychiatric_Drug_Development__Diagnosing_a_Crisis/